LIVIVO - Search results -

Search results

Result 1 - 10 of total 27

Search options

Article: A case of EBV-associated adrenal leiomyoma.

Takemoto, Takumasa / Kiriyama, Ikuko / Sugawara, Yoshifumi / Abe, Chie / Teramoto, Norihiro / Hashine, Katsuyoshi / Yoshida, Isao / Asagi, Akinori

Radiology case reports

2024 Volume 19, Issue 6, Page(s) 2224–2229

Abstract: Adrenal leiomyomas are rare and often reported as Epstein-Barr virus (EBV)-associated smooth muscle tumor (SMT) in association with EBV infection in immunocompromised patients. We experienced a case of right adrenal leiomyoma that was incidentally found ... ...

Abstract	Adrenal leiomyomas are rare and often reported as Epstein-Barr virus (EBV)-associated smooth muscle tumor (SMT) in association with EBV infection in immunocompromised patients. We experienced a case of right adrenal leiomyoma that was incidentally found in a man in his 70s. Computed Tomography (CT) showed a well-circumscribed mass of 3.1 cm in diameter in the right adrenal gland, which increased to 4.9 cm in diameter over 1 year. Preoperative diagnosis was difficult due to the lack of specific imaging findings. He had a history of diffuse large B-cell lymphoma (DLBCL) 8 years ago, and EBV had been detected in his blood. EBV-encoded small RNA(EBER) in situ hybridization (EBER-ISH) of the right adrenal leiomyoma was positive, and the final diagnosis was EBV-associated leiomyoma.
Language	English
Publishing date	2024-03-16
Publishing country	Netherlands
Document type	Case Reports
ZDB-ID	2406300-9
ISSN	1930-0433
ISSN	1930-0433
DOI	10.1016/j.radcr.2024.02.044
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Characteristic distribution of maculopapular rash caused by gemcitabine-based chemotherapy.

Tohyama, Mikiko / Asagi, Akinori / Nakasya, Akio / Iuchi, Shunsuke / Hashine, Katsuyoshi

The Journal of dermatology

2020 Volume 48, Issue 2, Page(s) 215–218

Abstract: Skin toxicity induced by gemcitabine, a chemotherapeutic agent, is not rare, but is usually mild. However, the occurrence of moderate to severe skin rash has been reported in patients treated with combinations of gemcitabine and other anticancer drugs. ... ...

Abstract	Skin toxicity induced by gemcitabine, a chemotherapeutic agent, is not rare, but is usually mild. However, the occurrence of moderate to severe skin rash has been reported in patients treated with combinations of gemcitabine and other anticancer drugs. The aim of this study was to assess the characteristics of rash caused by gemcitabine-based chemotherapy. We analyzed 12 patients who developed maculopapular rash over more than 10% of their body surface following gemcitabine-based chemotherapy. Maculopapular rash appeared at 6.3 ± 1.3 days after the first administration in eight patients and the second administration in four patients. In two patients, the rash was localized on the lateral aspect of the trunk. The other 10 patients showed various degrees of rash on the chest and abdomen, in addition to the lateral aspect of the trunk. However, rash was absent on the upper and middle back in almost all patients. After the rash disappeared, gemcitabine was re-administrated in eight patients. They continued the therapy with no or only mild rash relapse. In conclusion, maculopapular rash caused by gemcitabine-based chemotherapy shows biased distribution to frontal and lateral sites of the trunk, which may be informative for consecutive chemotherapy.
MeSH term(s)	Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Deoxycytidine/adverse effects ; Deoxycytidine/analogs & derivatives ; Drug Administration Schedule ; Exanthema/chemically induced ; Exanthema/diagnosis ; Humans
Chemical Substances	Deoxycytidine (0W860991D6) ; gemcitabine (B76N6SBZ8R)
Language	English
Publishing date	2020-11-11
Publishing country	England
Document type	Journal Article
ZDB-ID	800103-0
ISSN	1346-8138 ; 0385-2407
ISSN (online)	1346-8138
ISSN	0385-2407
DOI	10.1111/1346-8138.15654
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.B 1950: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Prospective observational study of zinc deficiency symptoms during first-line chemotherapy for gastric and colorectal cancer.

Sakaguchi, Chihiro / Nishina, Tomohiro / Kono, Yoshiyasu / Hino, Kaori / Asagi, Akinori / Ohno, Yoshinori / Kajiwara, Takeshi / Nadano, Seijin / Yamashita, Natsumi / Tohyama, Mikiko / Hyodo, Ichinosuke / Okada, Hiroyuki / Otsuka, Motoyuki

Journal of gastrointestinal oncology

2023 Volume 14, Issue 6, Page(s) 2384–2394

Abstract: Background: Zinc deficiency during long-term chemotherapy and its related symptoms, including skin rash, taste disorders, and oral mucositis, have not been sufficiently investigated.: Methods: This prospective observational study enrolled patients ... ...

Abstract	Background: Zinc deficiency during long-term chemotherapy and its related symptoms, including skin rash, taste disorders, and oral mucositis, have not been sufficiently investigated. Methods: This prospective observational study enrolled patients with gastric and colorectal cancer who underwent standard first-line chemotherapy. According to the Practice Guidelines for Zinc Deficiency, zinc deficiency is defined as a serum level of <60 µg/dL. Serum zinc levels were measured before and after (1, 3, and 6 months) chemotherapy, and symptoms were assessed using the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events version 1.0. Repeated measures were analyzed using a generalized linear mixed model. Results: Of the 61 enrolled patients, 48 who underwent standard first-line chemotherapy with fluoropyrimidine plus oxaliplatin were analyzed. Zinc deficiency was observed in 18 patients (38%) before chemotherapy. The least-squares means of serum zinc levels significantly decreased at 3 and 6 months of chemotherapy in 30 patients without zinc deficiency at the start of chemotherapy (both P<0.01) but not in 18 with zinc deficiency at the beginning. Changes in serum zinc levels during chemotherapy negatively correlated with changes in taste, rash, and itching (all P<0.04) in patients without zinc deficiency before treatment initiation. Conclusions: Serum zinc levels decreased during chemotherapy in zinc-non-deficient patients at the beginning of chemotherapy and correlated with taste changes, skin rash, and itching. Therefore, investigating whether zinc supplementation ameliorates these symptoms is necessary.
Language	English
Publishing date	2023-11-23
Publishing country	China
Document type	Journal Article
ZDB-ID	2594644-4
ISSN	2219-679X ; 2078-6891
ISSN (online)	2219-679X
ISSN	2078-6891
DOI	10.21037/jgo-23-517
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Development of a nomogram to predict survival in advanced biliary tract cancer.

Scientific reports

2023 Volume 13, Issue 1, Page(s) 21548

Abstract: The prognosis of advanced biliary tract cancer (BTC) patients remains poor due to limited efficacy of chemotherapy and difficulties in management. Thus, prediction of survival is crucial for the clinical management of advanced BTC. The aim was to develop ...

Abstract	The prognosis of advanced biliary tract cancer (BTC) patients remains poor due to limited efficacy of chemotherapy and difficulties in management. Thus, prediction of survival is crucial for the clinical management of advanced BTC. The aim was to develop and validate a nomogram to predict 6-month and 12-month survival in advanced BTC patients treated with chemotherapy. A multivariable Cox regression model was used to construct a nomogram in a training set (JCOG1113, a phase III trial comparing gemcitabine plus S-1 [GS] and gemcitabine plus cisplatin, n = 351). External validity of the nomogram was assessed using a test set (JCOG0805, a randomized, phase II trial comparing GS and S-1 alone, n = 100). Predictive performance was assessed in terms of discrimination and calibration. The constructed nomogram included lymph node metastasis, liver metastasis, carbohydrate antigen 19-9, carcinoembryonic antigen, albumin, and C-reactive protein. Uno's concordance index was 0.661 (95% confidence interval [CI] 0.629-0.696) in the training set and 0.640 (95% CI 0.566-0.715) in the test set. The calibration plots for 6-month and 12-month survival showed good agreement in the two analysis sets. The present nomogram can facilitate prediction of the prognosis of advanced BTC patients treated with chemotherapy and help clinicians' prognosis-based decision-making.
MeSH term(s)	Humans ; Nomograms ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Gemcitabine ; Deoxycytidine ; Prognosis ; Cisplatin/therapeutic use ; Biliary Tract Neoplasms/pathology
Chemical Substances	Gemcitabine ; Deoxycytidine (0W860991D6) ; Cisplatin (Q20Q21Q62J)
Language	English
Publishing date	2023-12-06
Publishing country	England
Document type	Journal Article
ZDB-ID	2615211-3
ISSN	2045-2322 ; 2045-2322
ISSN (online)	2045-2322
ISSN	2045-2322
DOI	10.1038/s41598-023-48889-6
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Postoperative Treatment of Resectable Pancreatic Cancer With Positive Peritoneal Lavage Cytology: A Multicentre Retrospective Study.

Todaka, Akiko / Nara, Satoshi / Motoi, Fuyuhiko / Morinaga, Soichiro / Toshiyama, Reishi / Higuchi, Ryota / Konishi, Masaru / Shirakawa, Hirofumi / Tsumura, Hidetaka / Okuyama, Hiroyuki / Nagano, Hiroaki / Shioji, Kazuhiko / Sugimachi, Keishi / Asagi, Akinori / Mizuno, Nobumasa / Furuse, Junji

Anticancer research

2022 Volume 42, Issue 2, Page(s) 893–902

Abstract: Background/aim: We aimed to evaluate pancreatic cancer (PC) with positive peritoneal lavage cytology (CY1) outcomes following a change in adjuvant therapy.: Patients and methods: The clinicopathological data of patients with pancreatic adenocarcinoma ...

Abstract	Background/aim: We aimed to evaluate pancreatic cancer (PC) with positive peritoneal lavage cytology (CY1) outcomes following a change in adjuvant therapy. Patients and methods: The clinicopathological data of patients with pancreatic adenocarcinoma with CY1 at 14 institutions, between 2007 and 2015, were collected and analyzed. Results: Of the 124 eligible patients, 114 underwent macroscopically curative resection. Of the 114 patients, 80 (70%) did not have early recurrence and received postoperative chemotherapy that was S-1 in 43 (54%), gemcitabine in 31 (39%), and others in six (7%). The median overall survival was 21.0 months in S-1 and 19.2 in gemcitabine therapy (p=0.23), whereas the median relapse-free survival was 10.2 and 7.1 months (p=0.03), respectively. Conclusion: Following the change in adjuvant therapy, most PC patients with CY1 who underwent macroscopically curative resection received S-1; however, it was insufficient. Further development of postoperative chemotherapy is required.
MeSH term(s)	Adult ; Aged ; Aged, 80 and over ; Chemotherapy, Adjuvant ; Deoxycytidine/analogs & derivatives ; Deoxycytidine/therapeutic use ; Drug Combinations ; Female ; Humans ; Japan/epidemiology ; Male ; Middle Aged ; Oxonic Acid/therapeutic use ; Pancreatectomy ; Pancreatic Neoplasms/drug therapy ; Pancreatic Neoplasms/mortality ; Pancreatic Neoplasms/pathology ; Pancreatic Neoplasms/surgery ; Peritoneal Lavage ; Peritoneal Neoplasms/drug therapy ; Peritoneal Neoplasms/mortality ; Peritoneal Neoplasms/secondary ; Survival Analysis ; Tegafur/therapeutic use ; Treatment Outcome
Chemical Substances	Drug Combinations ; Deoxycytidine (0W860991D6) ; S 1 (combination) (150863-82-4) ; Tegafur (1548R74NSZ) ; Oxonic Acid (5VT6420TIG) ; gemcitabine (B76N6SBZ8R)
Language	English
Publishing date	2022-01-29
Publishing country	Greece
Document type	Journal Article ; Multicenter Study
ZDB-ID	604549-2
ISSN	1791-7530 ; 0250-7005
ISSN (online)	1791-7530
ISSN	0250-7005
DOI	10.21873/anticanres.15547
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1642: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Comprehensive review of undifferentiated carcinoma of the pancreas: from epidemiology to treatment.

Japanese journal of clinical oncology

2023 Volume 53, Issue 9, Page(s) 764–773

Abstract: Undifferentiated carcinoma (UC) of the pancreas is a rare subtype of pancreatic cancer displaying no definitive direction of differentiation. UC has been reported as a highly aggressive malignant neoplasm, with a median overall survival of <1 year, ... ...

Abstract	Undifferentiated carcinoma (UC) of the pancreas is a rare subtype of pancreatic cancer displaying no definitive direction of differentiation. UC has been reported as a highly aggressive malignant neoplasm, with a median overall survival of <1 year, except for several surgical series. On the other hand, UC tissue sometimes contains non-neoplastic osteoclast-like giant cells (OGCs), and such cases have been reported to have relatively longer survival. Thus, the World Health Organization (WHO) classification histologically distinguishes UC with OGCs (UCOGCs) from UC, and UCs were subclassified into three subtypes: anaplastic UC, sarcomatoid UC and carcinosarcoma. However, still less is known about UC due to its rarity, and such situations lead to further difficulties in treatment for UC. To date, only surgical resection can offer curative treatment for patients with UC, and no clear evidence for chemotherapy exists for them. However, a retrospective cohort study and case reports showed that relatively promising results paclitaxel-containing regimens for treatment of patients with unresectable UC. Furthermore, high programmed cell death protein 1 expression has been reported in sarcomatoid UCs and UCOGCs, and promising responses to anti-programmed death-ligand 1 therapy have been described in case reports of UCOGCs. Recent advances in chemotherapeutic agents and molecular technologies are opening up the possibilities for expanded treatments.
MeSH term(s)	Humans ; Retrospective Studies ; Pancreatic Neoplasms/epidemiology ; Pancreatic Neoplasms/therapy ; Carcinoma/pathology ; Pancreas/surgery ; Pancreas/pathology
Language	English
Publishing date	2023-06-15
Publishing country	England
Document type	Review ; Journal Article
ZDB-ID	190978-2
ISSN	1465-3621 ; 0368-2811
ISSN (online)	1465-3621
ISSN	0368-2811
DOI	10.1093/jjco/hyad062
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1298: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: [Tolerability of Definitive Chemoradiotherapy in Elderly Patients with Esophageal Cancer].

Hino, Kaori / Kajiwara, Takeshi / Nishina, Tomohiro / Inoue, Tomonori / Yoshimatsu, Megumi / Sakaguchi, Chihiro / Nakasya, Akio / Nishide, Norifumi / Asagi, Akinori / Hasebe, Aki / Terao, Takashi / Hori, Shinichiro / Nadano, Seijin / Hamamoto, Yasushi / Kataoka, Masaaki / Tanimizu, Masahito

Gan to kagaku ryoho. Cancer & chemotherapy

2020 Volume 47, Issue 11, Page(s) 1577–1581

Abstract: Definitive chemoradiotherapy(CRT)for esophageal cancer is the standard treatment and alternative to surgery. However, the tolerability of CRT in elderly patients is not well known. In this study, we retrospectively analyzed 60 patients with esophageal ... ...

Abstract	Definitive chemoradiotherapy(CRT)for esophageal cancer is the standard treatment and alternative to surgery. However, the tolerability of CRT in elderly patients is not well known. In this study, we retrospectively analyzed 60 patients with esophageal cancer who were treated with CRT(5-FU 700 mg/m2, cisplatin 70 mg/m2, radiation 60 Gy)at our hospital between January 2015 and September 2017. The patients were divided into 2 groups: an elderly group comprising 16 patients aged >75 years and a non-elderly group comprising 44 patients aged <74 years. The relative dose intensity of cisplatin in the elderly group was significantly lower than that in the non-elderly group. Radiotherapy was successfully executed in both groups. More patients in the elderly(25%)than the non-elderly group(7%)developed pneumonitis, and all patients who developed severe pneumonitis in the elderly group died. Application of definitive CRT and irradiation methods in elderly patients with a subpleural reticular shadow should be carefully considered before initiating therapy.
MeSH term(s)	Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carcinoma, Squamous Cell/drug therapy ; Chemoradiotherapy/adverse effects ; Cisplatin/adverse effects ; Esophageal Neoplasms/pathology ; Fluorouracil/therapeutic use ; Humans ; Middle Aged ; Neoplasm Staging ; Patients ; Retrospective Studies ; Treatment Outcome
Chemical Substances	Cisplatin (Q20Q21Q62J) ; Fluorouracil (U3P01618RT)
Language	Japanese
Publishing date	2020-12-02
Publishing country	Japan
Document type	Journal Article
ZDB-ID	604842-0
ISSN	0385-0684
ISSN	0385-0684
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 2573: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: A Phase II Trial of Everolimus in Patients with Advanced Pancreatic Neuroendocrine Carcinoma Refractory or Intolerant to Platinum-Containing Chemotherapy (NECTOR Trial).

Okuyama, Hiroyuki / Ikeda, Masafumi / Okusaka, Takuji / Furukawa, Masayuki / Ohkawa, Shinichi / Hosokawa, Ayumu / Kojima, Yasushi / Hara, Hiroki / Murohisa, Gou / Shioji, Kazuhiko / Asagi, Akinori / Mizuno, Nobumasa / Kojima, Motohiro / Yamanaka, Takeharu / Furuse, Junji

Neuroendocrinology

2020 Volume 110, Issue 11-12, Page(s) 988–993

Abstract: Background: Platinum-containing regimens are widely used as first-line chemotherapy for unresectable pancreatic neuroendocrine carcinoma (NEC), but second-line chemotherapies have yet to be established.: Objectives: We evaluated the safety and ... ...

Abstract	Background: Platinum-containing regimens are widely used as first-line chemotherapy for unresectable pancreatic neuroendocrine carcinoma (NEC), but second-line chemotherapies have yet to be established. Objectives: We evaluated the safety and efficacy of everolimus in patients with pancreatic NEC refractory or intolerant to platinum-containing chemotherapy. Methods: This study was a prospective, multicenter, phase II trial in patients with pancreatic NEC after platinum-containing chemotherapy. Everolimus treatment was continued until disease progression or intolerable toxicity was observed. The primary endpoint was progression-free survival (PFS). Results: Participants comprised 25 patients. Median age was 63 years, median PFS was 1.2 months (95% confidence interval [CI] 0.9-3.1 months), median overall survival was 7.5 months (95% CI 3.1-13.5 months), overall response rate was 0%, and disease control rate was 39.1%. Common grade 3/4 adverse events were hyperglycemia (20%), thrombocytopenia (16%), and anemia (16%). Conclusion: The efficacy of everolimus was limited in patients with unresectable pancreatic NEC.
MeSH term(s)	Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/pharmacology ; Carcinoma, Neuroendocrine/drug therapy ; Drug-Related Side Effects and Adverse Reactions ; Everolimus/administration & dosage ; Everolimus/adverse effects ; Everolimus/pharmacology ; Female ; Humans ; Male ; Middle Aged ; Outcome Assessment, Health Care ; Pancreatic Neoplasms/drug therapy ; Platinum/therapeutic use ; Progression-Free Survival ; Prospective Studies
Chemical Substances	Antineoplastic Agents ; Platinum (49DFR088MY) ; Everolimus (9HW64Q8G6G)
Language	English
Publishing date	2020-01-02
Publishing country	Switzerland
Document type	Clinical Trial, Phase II ; Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
ZDB-ID	123303-8
ISSN	1423-0194 ; 0028-3835
ISSN (online)	1423-0194
ISSN	0028-3835
DOI	10.1159/000505550
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 531: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in Unresectable Pancreatic Cancer.

Internal medicine (Tokyo, Japan)

2022 Volume 61, Issue 15, Page(s) 2255–2261

Abstract: Objective S-1 and modified FOLFIRINOX (mFFX) were often used as the second-line chemotherapies after failure of gemcitabine plus nab-paclitaxel (GnP) in unresectable pancreatic cancer (UPC) until nanoliposomal irinotecan plus 5-fluorouracil/leucovorin ... ...

Abstract	Objective S-1 and modified FOLFIRINOX (mFFX) were often used as the second-line chemotherapies after failure of gemcitabine plus nab-paclitaxel (GnP) in unresectable pancreatic cancer (UPC) until nanoliposomal irinotecan plus 5-fluorouracil/leucovorin therapy was approved as an alternative in Japan in 2020. However, the clinical outcomes of S-1 and mFFX after GnP have scarcely been reported. Therefore, we retrospectively studied them. Methods We extracted the clinical data of 86 patients with UPC who received second-line chemotherapy after GnP between 2015 and 2020. Among the patients who had a good organ functions and no massive ascites, 41 patients treated with S-1 and 21 treated with mFFX were enrolled. Results Compared to S-1, mFFX tended to be used for younger patients with a good general condition (median age, 63 vs. 71 years, p<0.01; and performance status 0, 67% vs. 37%, p<0.05). The median progression-free and overall survival were similar between the S-1 (3.7 and 7.2 months, respectively) and mFFX (3.3 and 7.4 months, respectively) groups. The response rate in patients with measurable lesions was 4% (n=1/23) in the S-1 group and 17% (n=2/12) in the mFFX group. The incidence of grade 3 or 4 adverse events was 20% in the S-1 group and 57% (neutrophil count decreased in 43%) in the mFFX group (p<0.01). Conclusion S-1 and mFFX were both acceptable second-line chemotherapies after GnP therapy for UPC, although attention should be paid to myelosuppression during mFFX treatment. Further studies involving nanoliposomal irinotecan plus 5-fluorouracil/leucovorin therapy are necessary to facilitate the selection of the optimal regimen for each patient.
MeSH term(s)	Albumins/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Deoxycytidine/analogs & derivatives ; Fluorouracil ; Humans ; Irinotecan/adverse effects ; Leucovorin/adverse effects ; Middle Aged ; Oxaliplatin ; Paclitaxel/therapeutic use ; Pancreatic Neoplasms/pathology ; Retrospective Studies ; Gemcitabine ; Pancreatic Neoplasms
Chemical Substances	130-nm albumin-bound paclitaxel ; Albumins ; folfirinox ; Oxaliplatin (04ZR38536J) ; Deoxycytidine (0W860991D6) ; Irinotecan (7673326042) ; Paclitaxel (P88XT4IS4D) ; Leucovorin (Q573I9DVLP) ; Fluorouracil (U3P01618RT) ; Gemcitabine
Language	English
Publishing date	2022-08-01
Publishing country	Japan
Document type	Journal Article
ZDB-ID	32371-8
ISSN	1349-7235 ; 0021-5120 ; 0918-2918
ISSN (online)	1349-7235
ISSN	0021-5120 ; 0918-2918
DOI	10.2169/internalmedicine.8736-21
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 240: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Endoscopic duodenal stent placement versus gastrojejunostomy for unresectable pancreatic cancer patients with duodenal stenosis before introduction of initial chemotherapy (GASPACHO study): a multicenter retrospective study.

Azemoto, Nobuaki / Ueno, Makoto / Yanagimoto, Hiroaki / Mizuno, Nobumasa / Kawamoto, Yasuyuki / Maruki, Yuta / Watanabe, Kazuo / Suzuki, Rei / Kaneko, Junichi / Hisada, Yuya / Sato, Hiroki / Kobayashi, Satoshi / Miyata, Hideki / Furukawa, Masayuki / Mizukami, Takuro / Miwa, Haruo / Ohno, Yoshinori / Tsuji, Kunihiro / Tsujimoto, Akiko /

Nagano, Hiroaki / Okuyama, Hiroyuki / Asagi, Akinori / Okano, Naohiro / Ishii, Hiroshi / Morizane, Chigusa / Ikeda, Masafumi / Furuse, Junji

Japanese journal of clinical oncology

2022 Volume 52, Issue 2, Page(s) 134–142

Abstract: Background: Endoscopic duodenal stent placement is an alternative technique to gastrojejunostomy for gastric outlet obstruction due to pancreatic cancer. We compared the efficacy of endoscopic duodenal stent placement with that of gastrojejunostomy for ... ...

Abstract	Background: Endoscopic duodenal stent placement is an alternative technique to gastrojejunostomy for gastric outlet obstruction due to pancreatic cancer. We compared the efficacy of endoscopic duodenal stent placement with that of gastrojejunostomy for treating patients with pancreatic cancer who are candidates for intensive combination chemotherapies as the first line of treatment. Methods: This retrospective observational study included 100 patients from 18 institutions in Japan. Inclusion criteria were as follows: (1) cytologically or histologically confirmed adenocarcinoma of the pancreas, (2) good performance status, (3) gastric outlet obstruction scoring system score of 0-1 and (4) no history of treatment for pancreatic cancer. Results: There was no significant difference in the background characteristics of patients in the endoscopic duodenal stent placement (n = 57) and gastrojejunostomy (n = 43) groups. The median overall survival in the endoscopic duodenal stent placement and gastrojejunostomy groups was 5.9 and 6.0 months, respectively. Clinical success was achieved in 93 cases; the median time to food intake resumption was significantly shorter in the endoscopic duodenal stent placement group (median: 3 days, n = 54) than in the gastrojejunostomy group (median: 5 days, n = 43). Chemotherapy was introduced in 63% of the patients in both groups after endoscopic duodenal stent placement or gastrojejunostomy. Chemotherapy was started earlier in the endoscopic duodenal stent placement group (median: 14 days) than in the gastrojejunostomy (median: 32 days) group. Conclusions: Endoscopic duodenal stent placement showed similar or better clinical outcomes than gastrojejunostomy. Thus, it might be a promising option in patients with good performance status.
MeSH term(s)	Duodenal Obstruction ; Gastric Bypass ; Humans ; Intestinal Atresia ; Palliative Care ; Pancreatic Neoplasms/complications ; Pancreatic Neoplasms/drug therapy ; Retrospective Studies ; Stents ; Treatment Outcome
Language	English
Publishing date	2022-12-30
Publishing country	England
Document type	Journal Article ; Multicenter Study ; Observational Study
ZDB-ID	190978-2
ISSN	1465-3621 ; 0368-2811
ISSN (online)	1465-3621
ISSN	0368-2811
DOI	10.1093/jjco/hyab194
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1298: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito